Abstract:Cytotoxic T lymphocytes (CTL) are a major factor in the control of HIV replication. CTL arise in acute infection, causing escape mutations to spread rapidly through the population of infected cells. As a result, the virus develops partial resistance to the immune response. The factors controlling the order of mutating epitope sites are currently unknown and would provide a valuable tool for predicting conserved epitopes. In this work, we adapt a well-established mathematical model of HIV evolution under dynamical selection pressure from multiple CTL clones to include partial impairment of CTL recognition, [Formula: see text], as well as cost to viral replication, [Formula: see text]. The process of escape is described in terms of the cost-benefit tradeoff of escape mutations and predicts a trajectory in the cost-benefit plane connecting sequentially escaped sites, which moves from high recognition loss/low fitness cost to low recognition loss/high fitness cost and has a larger slope for early escapes than for late escapes. The slope of the trajectory offers an interpretation of positive correlation between fitness costs and HLA binding impairment to HLA-A molecules and a protective subset of HLA-B molecules that was observed for clinically relevant escape mutations in the Pol gene. We estimate the value of [Formula: see text] from published experimental studies to be in the range (0.01-0.86) and show that the assumption of complete recognition loss ([Formula: see text]) leads to an overestimate of mutation cost. Our analysis offers a consistent interpretation of the commonly observed pattern of escape, in which several escape mutations are observed transiently in an epitope. This non-nested pattern is a combined effect of temporal changes in selection pressure and partial recognition loss. We conclude that partial recognition loss is as important as fitness loss for predicting the order of escapes and, ultimately, for predicting conserved epitopes that can be targeted by vaccines.

Selection and Neutral Mutations Drive Pervasive Mutability Losses in Long-Lived Anti-HIV B-Cell Lineages

Intrapatient Evolutionary Dynamics in an Individual Infected with HIV-1 CRF01_AE Who Experienced Periods of Treatment Failure

Deleterious synonymous mutations hitchhike to high frequency in HIV-1 env evolution

Codon Bias and Mutability in HIV Sequences

Affinity Maturation In An Hiv Broadly Neutralizing B-Cell Lineage Through Reorientation Of Variable Domains

Sequence Intrinsic Somatic Mutation Mechanisms Contribute to Affinity Maturation of Vrc01-Class Hiv-1 Broadly Neutralizing Antibodies

In-vivo mutation rates and fitness landscape of HIV-1

The Route of HIV Escape from Immune Response Targeting Multiple Sites Is Determined by the Cost-Benefit Tradeoff of Escape Mutations

Comparison of Antibody Repertoires Produced by HIV-1 Infection, Other Chronic and Acute Infections, and Systemic Autoimmune Disease

Selection of Immunoglobulin Elbow Region Mutations Impacts Interdomain Conformational Flexibility in HIV-1 Broadly Neutralizing Antibodies

HIV-1 adaptation studies reveal a novel Env-mediated homeostasis mechanism for evading lethal hypermutation by APOBEC3G

Neutralization Sensitivity of HIV-1 CRF07_BC From an Untreated Patient With a Focus on Evolution Over Time

Mutability and hypermutation antagonize immunoglobulin codon optimality

Contribution of Rare Mutational Outcomes to Broadly Neutralizing Antibodies

Rare HLA drive additional HIV evolution compared to more frequent alleles.

Viral evolution under the pressure of an adaptive immune system - optimal mutation rates for viral escape

Loss and Recovery of Genetic Diversity in Adapting Populations of HIV

Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth

Autoreactivity and Broad Neutralization of Antibodies Against HIV-1 Are Governed by Distinct Mutations: Implications for Vaccine Design Strategies

Host-specific Driving Force in Human Immunodeficiency Virus Type 1 Evolution in Vivo.

Recombination Rate and Selection Strength in HIV Intra-patient Evolution